OOIR: Observatory of International Research

Papers

(The TQCC of Blood Coagulation & Fibrinolysis is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
The role of thrombin in haemostasis	35
Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case	16
HJHS 2.1 and HEAD-US assessment in the hemophilic joints: How do their findings compare?	15
Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis	14
Outcomes of patients with thromboembolic events following coronavirus disease 2019 AstraZeneca vaccination: a systematic review and meta-analysis	14
Coronavirus disease 2019 and coagulopathy: other prothrombotic coagulation factors	13
d-Dimer serum levels as a biomarker associated for the lethality in patients with coronavirus disease 2019: a meta-analysis	13
Blood biocompatibility enhancement of biomaterials by heparin immobilization: a review	12
Antiphospholipid antibodies in patients with coronavirus disease 2019 infection hospitalized in conventional unit	11
Reduced cleavage of von willebrand factor by ADAMTS13 is associated with microangiopathic acute kidney injury following trauma	11
Periodontitis, coronary heart disease and myocardial infarction: treat one, benefit all	11
The incidence of venous thromboembolic events in trauma patients after tranexamic acid administration: an EAST multicenter study	11
Tranexamic acid is associated with reduced complement activation in trauma patients with hemorrhagic shock and hyperfibrinolysis on thromboelastography	11
Vascular activation is a strong predictor of mortality in coronavirus disease 2019 patients on the ICU	10
Evaluating the potential benefits of the extravascular pool of factor IX	10
Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm?	9
Coronavirus disease 2019 in patients with chronic immune thrombocytopenia on thrombopoietin receptor agonists: new perspectives and old challenges	9
A mild deficiency of ADAMTS13 is associated with severity in COVID-19: comparison of the coagulation profile in critically and noncritically ill patients	9
The physiology of hemostasis	9
High prevalence of overweight/obesity in adult persons with hemophilia in Utah and a review of the literature	8
‘Pulmonary thrombosis in situ’: risk factors, clinic characteristics and long-term evolution	8
Evaluation of analytic and clinical performance of thrombin–antithrombin complex and d-dimer assay in prognosis of acute ischemic stroke	8
Relationship between serum soluble endothelial protein C receptor level and COVID-19 findings	8
Effectiveness of intravenous immunoglobulin use in heparin-induced thrombocytopenia	8
ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107 720 doses of ChAdOx1 vaccination in Thailand	8

First report of COVID-19 vaccine induced flare of compensated congenital thrombotic thrombocytopenic purpura	8
Human coagulation factor IX: a systematic review of its characteristics	7
Viscoelastic hemostasis assays in septic, critically ill coronavirus disease 2019 patients: a practical guide for clinicians	7
Postpartum bleeding in women with inherited bleeding disorders: a matched cohort study	7
Clinical safety and efficacy of thrombolytic therapy with low-dose prolonged infusion of tissue type plasminogen activator in patients with intermediate-high risk pulmonary embolism	7
Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States	7
Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review	7
Application of microfluidic chip technology to study the inhibitory effect of tetramethylpyrazine on platelet aggregation, activation, and phosphatidylserine exposure mediated by pathological high she	7
Comparison of different activators of coagulation by turbidity analysis of hereditary dysfibrinogenemia and controls	7
Acquired factor V inhibitor in the setting of coronavirus disease 2019 infection	7
Platelet hyperaggregability and venous thrombosis risk: results from the RETROVE project	7
Complete hemostasis achieved by factor XIII concentrate administration in a patient with bleeding after teeth extraction as a complication of aplastic anemia and chronic disseminated intravascular coa	6
Tranexamic acid rapidly inhibits fibrinolysis, yet transiently enhances plasmin generation in vivo	6
Nonimmune-acquired factor XIII deficiency: a cause of high volume and delayed postoperative hemorrhage	6
Factors associated with deep venous thrombosis in patients infected with coronavirus disease 2019: a meta-analysis	6
Immune thrombocytopenia: options and new perspectives	6
Derangement of the coagulation process using subclinical markers and viscoelastic measurements in critically ill patients with coronavirus disease 2019 pneumonia and non-coronavirus disease 2019 pneum	6
How to use low-molecular-weight heparin to treat neonatal thrombosis in clinical practice	6
Effective tranexamic acid concentration for 95% inhibition of tissue-type plasminogen activator-induced hyperfibrinolysis in full-term pregnant women: a prospective interventional study	6
Current methods of measuring platelet activity: pros and cons	6
A case-report of two patients with hereditary protein S deficiency treated by rivaroxaban	5
A prospective cohort study of catheter-related thrombosis in cancer patients treated with 1 month of anticoagulation after catheter removal	5
System performance evaluation of the cobas t 711 and cobas t 511 coagulation analyzers in routine laboratory settings	5
Management of surgery, menorrhagia and child-birth for patients with unclassified bleeding disorders: a systematic review of cohort studies	5
Subcutaneous injection of mRNA vaccines against severe acute respiratory syndrome coronavirus 2: an option for severe bleeding disorders or anticoagulated patients?	5
Harmonizing factor assay-related testing performed in a large laboratory network	5
Standard and derived rotational thromboelastometry parameters for prediction of disseminated intravascular coagulation in septic patients	5
Global sources of cryoprecipitate demonstrate variability in coagulant factor levels and functional hemostasis	5
Clinical characteristics and outcomes of patients with isolated pulmonary embolism	5
Efficacy and safety of eltrombopag during conception and first trimester of pregnancy in a case of refractory severe immune thrombocytopenia	5
A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism	5
Assessment of endothelial progenitor cells, VEGF-A and SDF-1α in Hodgkin's lymphoma	5
Increased resistance to fibrinolysis activation in patients with coronavirus disease 2019: a case series	5
Direct oral anticoagulant neutralization by activated charcoal DOAC-Remove for thrombophilia screening	5
Apoptosis in platelets from adult patients with chronic idiopathic thrombocytopenic purpura	4
Evaluation of 4Ts score inter-rater agreement in patients undergoing evaluation for heparin-induced thrombocytopenia	4
Age, sex and racial differences in fibrin formation and fibrinolysis within the healthy population	4
Psychological complications among patients with congenital bleeding disorders	4
Mannose-binding lectin-associated serine protease-1 cleaves plasminogen and plasma fibronectin: prefers plasminogen over known fibrinogen substrate	4
Interaction of glycated and acetylated human α2-antiplasmin with fibrin clots	4
Interleukin-10 levels and the risk of thromboembolism according to COMPASS-Cancer associated thrombosis score in breast cancer patients prior to undergoing doxorubicin-based chemotherapy	4
Weekly low-dose recombinant factor VIIa prophylaxis in Glanzmann thrombasthenia	4
General concepts on hemophilia A and on women carrying the disease	4
Hemophilia carriers: quality of life and management at different life stages	4
A bispecific antibody demonstrates limited measurability in routine coagulation assays	4
Direct oral anticoagulants in patients with antiphospholipid syndrome: a retrospective study in a real-life patient cohort	4
Lupus anticoagulant activity and thrombosis post COVID-19 vaccination	4
Type II antithrombin deficiency caused by a novel missense mutation (p.Leu417Gln) in a Chinese family	4
In-vitro thromboelastographic characterization of reconstituted whole blood utilizing cryopreserved platelets	4
Severe hyperphosphatasemia and severe acute respiratory syndrome coronavirus 2 infection in children	4

Thrombin generation assay: the present and the future	4
Chronic pain in patients with hemophilia: is it preventable?	4
Homozygous methylentetrahydrofolate reductase C667T genotype anticipates age at venous thromboembolism by one decade	4
Interference of icterus on plasma D-dimer levels measured using immunoturbidimetric assays	4
Tranexamic acid versus aminocapróic acid in multiple doses via the oral route for the reduction of postoperative bleeding in total primary hip arthroplasty: a prospective, randomized, double-blind, co	3
A challenging case of heparin-induced skin necrosis without thrombocytopenia	3
The association between plasminogen activator inhibitor type-1 and clinical outcome in paediatric sepsis	3
Microparticles: a link to increased thrombin generation	3
Difficulty in controlling heavy menstrual bleeding at menarche in a patient with Glanzmann's thrombasthenia	3
The impact of atorvastatin on dabigatran plasma levels in patients with atrial fibrillation	3
Deep intronic F8 c.5999-27A>G variant causes exon 19 skipping and leads to moderate hemophilia A	3
Very low-dose recombinant Factor VIIa administration for cardiac surgical bleeding reduces red blood cell transfusions and renal risk: a matched cohort study	3
Effects of Momordica charantia exosomes on platelet activation, adhesion, and aggregation	3
A novel heterozygous mutation (γIIe367Thr) causes congenital dysfibrinogenemia in a Chinese family	3
Enzymatic deinduction phenomenon and clinical implications with a focus on direct-acting oral anticoagulants	3
Effect of remote ischemic preconditioning on fibrin formation and metabolism in patients undergoing hip fracture surgery: a randomized clinical trial	3
Use of direct oral anticoagulants in cerebral venous thrombosis: a systematic review	3
In-vitro assessment of the effects of fibrinogen, recombinant factor VIIa and factor XIII on trauma-induced coagulopathy	3
New developments in the diagnosis of primary immune thrombocytopenia	3
Rapamycin induces megakaryocytic differentiation through increasing autophagy in Dami cells	3
Anticoagulation management post-transjugular intrahepatic portosystemic shunt in portal hypertension associated with myeloproliferative neoplasms	3
Soluble thrombomodulin and cardiovascular disease risk factors in Japanese children	3
Significant difference between coagulation parameters and clinicopathological characteristics in breast cancer	3
Use of thrombolytic agents to treat neonatal thrombosis in clinical practice	3
Spinal epidural hematoma in a child with hemophilia A with high titer inhibitors and follow-up with prophylactic emicizumab: case report and literature review	3
Challenges and concerns of patients with congenital bleeding disorders affected by coronavirus disease 2019	3
Cangrelor for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia: it is not so easy	3
Thrombosis risk of Alport syndrome patients: evaluation of cardiological, clinical, biochemical, genetic and possible causes of inherited thrombophilia and identification of a novel COL4A3 variant	3
Gene therapy for hemophilias: the end of phenotypic testing or the start of a new era?	3
Reversal of factor Xa inhibitors associated intracranial haemorrhage at a tertiary medical centre	3
Analysis of phenotype and genotype of a family with hereditary coagulation factor V deficiency caused by the compound heterozygous mutations	3
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report	3